All GLG News Analyses Filed Under: Endocrinology

    Both of Dr. Steven Nissen’s publications are meta-analysis, implying a weakness in their sampling.  In my opinion, more refined studies with larger sample sizes and standardized measurements with Actos, Avandia and placebo or other medications need to be evaluated. ...

With the growth of bariatric procedures and the increased recognition of the health benefits associated with massive weight loss, more insurance providers are beginning to cover bariatric procedures. The problems arise when these patients present to their plastic surgeons after their weight loss and...

The fewer the injections, the more market share if all else is the same. We will await to see how needle size will affect LAR acceptance. My estimate is that it will absolutely not. Patients never asked what the size of the needle was prior to initiation of BYETTA bid--they just heard "weight loss and...

OADs such as sulfonylureas and glitinides are being displaced today with the advent of sitagliptin for those who have coverage for this medication.

Although the pill would be effective in lowering cholesterol and triglycerides, there is no outcome data yet to show benefit comparable to Lipitor in lowering cardiovascular events. There is a report of an observational study with simvastatin, another lipid lowering drug, which shows 30% REDUCTION in cardiovascular...

Liraglutide will steal some market share from the leader, exenatide, but if exenatide comes out in a once a week formulation and other similar products even less often, the market will shift again.

This article is important because it highlights the potential for a drug that will be well received.  The combination of a statin and a fibrate is often used in clinical practice to achieve target lipid levels and a pill that would combine these two drugs would be very practical.  The only...

This combination will clearly cover the lipid abnormalities found in the metabolic syndrome and most diabetics. As long as there are no serious adverse effects from the combination it should have a clear niche in the market.

Fibrates plus statins provide much better control of the 3 major components of cholesterol - LDL-C, HDL-C and Tryglycerides - then either agent alone. The combination of fibrates and statins are safe and effective (providing the fibrate is fenofibrate and not gemfibrozil). ABT-335 is a newer formulation...

This article is relevant because of the concept of combining statins with other agents is going to become the norm for "next" generation lipid agents. The question is which combo will be doctors prescribe?